{
    "root": "cdf96e89-c6a0-4f0b-983e-b10681d969fb",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Heparin sodium",
    "value": "20240623",
    "ingredients": [
        {
            "name": "HEPARIN SODIUM",
            "code": "ZZ45AB24CA"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "Heparin sodium injection is indicated for: \n                  \n                     \n                        •Prophylaxis and treatment of venous thrombosis and pulmonary embolism; \n                     \n                        •Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; \n                     \n                        •Atrial fibrillation with embolization; \n                     \n                        •Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); \n                     \n                        •Prevention of clotting in arterial and cardiac surgery; \n                     \n                        •Prophylaxis and treatment of peripheral arterial embolism. \n                     \n                        •Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.",
    "contraindications": "Recommended Adult Dosages: • Therapeutic Anticoagulant Effect with Full-Dose Heparin † ( 2.3 ) Deep Subcutaneous (Intrafat) Injection Use a different site for each injection Initial Dose 5,000 units by intravenous injection followed by 10,000 to 20,000 units of a concentrated solution, subcutaneously Every 8 hours or Every 12 hours 8,000 to 10,000 units of a concentrated solution 15,000 to 20,000 units of a concentrated solution Intermittent Intravenous Injection Initial dose 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Every 4 to 6 hours 5,000 to 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Intravenous Infusion Initial dose 5,000 units by intravenous injection Continuous 20,000 to 40,000 units/24 hours in 1,000 mL of 0.9% Sodium Chloride Injection, USP (or in any compatible solution) for infusion † Based on 150 lb (68 kg) patient. Adjust dose based on laboratory monitoring.",
    "warningsAndPrecautions": "Heparin sodium injection, USP (porcine) contains parabens and is available as follows:\n                  NDC 67457-373-99: 20,000 USP units per mL, 1 mL multi-dose vial packaged in 25’s carton \n                  Use only if solution is clear and seal intact. Do not use if solution is discolored or contains a precipitate. \n                  This container closure is not made from natural rubber latex.\n                  \n                     STORAGE: \n                  \n                  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].",
    "adverseReactions": "The use of heparin sodium injection is contraindicated in patients with the following conditions: \n                  \n                     \n                        •History of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis [see Warnings and Precautions (5.3)]; \n                     \n                        •Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see Adverse Reactions (6.1)]; \n                     \n                     \n                        •In whom suitable blood coagulation tests, e.g., the whole blood clotting time, partial thromboplastin time, etc., cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin); \n                     \n                        •An uncontrolled active bleeding state [see Warnings and Precautions (5.4)], except when this is due to disseminated intravascular coagulation."
}